Using this metric, we found the relative proportion of MEPs (proportion MEPs/CD34+CD10-CD38+ cells) to be significantly reduced in both patients with low-risk MDS and MDS-EB as compared to control patients (S1 Fig). This evidence concerns the gene CD38 and myelodysplastic syndrome.